| Value | ₹9.15 Cr |
|---|---|
| Execution period | Within one month |
BSE filing, BSE: 544542. Summary written from the filing by ALFA Finder's alert engine.
Justo Realfintech Ltd: key numbers
- Share price
- ₹81.00
- Market cap
- ₹152.3 Cr
- Revenue (annual)
- ₹91.78 Cr
- Net profit (annual)
- ₹19.21 Cr
- P/E (TTM)
- 7.9×Sector 35.3×
- Promoter holding
- 39.49%
- FII holding
- 0.16%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Justo Realfintech Ltd
All →Justo Realfintech Other Announcement
Justo Realfintech submitted the Monitoring Agency Report for the quarter ended June 30, 2026, as required under SEBI (LODR) Regulations.
Justo Realfintech Price Movement Clarification
Justo Realfintech Limited clarified that recent equity share price movements are driven by market forces. The company confirms no undisclosed price-sensitive information or impending material developments exist.
Justo Realfintech Earnings Call: Key Takeaways
Justo Realfintech is a tech-driven real estate mandate firm shifting from a regional player to a pan-India powerhouse through its acquisition of the Chestertons India franchise.
Justo Realfintech Management Change
Mr. Nitin Pardeshi has resigned as Director of Sales & Marketing at Justo Realfintech Limited. He will be relieved from his duties effective May 30, 2026.
Justo Realfintech Management Change
Justo Realfintech appointed Ronak Jhuthawat & Co. as Secretarial Auditors and re-appointed SKHD and Associates as Internal Auditors. These appointments ensure continued regulatory and internal compliance.
- Execution
- 5 years (Secretarial Auditor); 1 year (Internal Auditor)
Justo Realfintech H2 FY26 Results: Net Profit ₹13.2 Cr, Up 65.0% YoY
Justo Realfintech Ltd reported revenue from operations of ₹55.1 Cr (+30.6% YoY) and net profit of ₹13.2 Cr (+65.0% YoY) for H2 FY26.
- Key figure
- Net profit ₹13.2 Cr · +65.0% YoY
Other merger & restructuring announcements
All →Aurobindo Pharma Merger & Restructuring Worth ₹29 Cr
Aurobindo Pharma approved transferring 100% of Auro Pharma LLC, Russia, between wholly owned subsidiaries. Cash consideration is about INR 29 crore, subject to adjustments.
- Value
- ₹29.00 Cr
- Execution
- 60-90 days
Choice International Merger & Restructuring Worth ₹1.27 Cr
Choice International sold a unit or subsidiary to Arrowbridge Trade for Rs.1.275 Crore in cash. The buyer is unrelated and the deal is at arm's length.
- Value
- ₹1.27 Cr
Shringar House of Mangalsutra Merger & Restructuring Worth ₹5 Cr
Shringar House of Mangalsutra will incorporate a wholly owned jewellery subsidiary, subscribing Rs 5 Crore in cash. The subsidiary becomes a related party once formed.
- Value
- ₹5.00 Cr
HEG Advanced Materials Merger & Restructuring Worth ₹10.12 Cr
HEG Advanced Materials closed LNJ Trading FZCO, its Dubai-based wholly owned subsidiary, as part of overseas structure rationalisation. The filing quantifies the effect at AED 4,048,000.
- Value
- ₹10.12 Cr
Saregama India Merger & Restructuring
Saregama India's board approved closing its wholly owned Dubai subsidiary, Saregama FZE, which has no ongoing operations. The closure is not expected to materially affect business operations.
Jindal Poly Films Merger & Restructuring
Jindal Poly Films' step-down subsidiary, JPF API Laminates UK Limited, was dissolved effective November 3, 2026. It has ceased to be a subsidiary of the company.